CD8+ T-cells have been shown to secrete soluble factors that can effectively inhibit HIV replication. Researchers at Mount Sinai, led by Dr. Mary Klotman have identified and characterized key products from CD8+ cells that not only enhance the understanding of the HIV life cycle but may also lead to a whole new class of treatment of HIV. These small proteins have been shown to be effective in reducing, eliminating, or preventing HIV infection in cell based assays.
Current Development Status
- Validation in cell models
Applications
- Novel treatments for HIV
Publications
- Mosoian, A. et al “CD8+ Cell Lines Isolated from HIV-1-Infected Children have Potent Soluble HIV-1 Inhibitory Activity that Differs from b-Chemokines”, Viral Immunology, 2000, 13, (4), 481-495.
Patent Status
- US Patent 6,358,511 (issued)
Contact
William Chiang, PhD
Business Development Director
Mount Sinai Innovation Partners | Icahn School of Medicine at Mount Sinai
Phone: 646.605.7309